The latest announcement is out from Homology Medicines Inc (FIXX).
Homology Medicines, Inc. has successfully completed a merger with Legacy Q32, with Legacy Q32 surviving as a wholly-owned subsidiary, transforming Homology into Q32 Bio Inc., a clinical-stage biotech company. Following the merger, a reverse stock split was executed at a 1:18 ratio, and Homology’s stockholders approved a significant issuance of common stock to Legacy Q32’s stockholders. Post-merger, the combined entity’s focus is on developing treatments for autoimmune and inflammatory diseases. The company’s stock commenced trading under the new ticker symbol “QTTB” on The Nasdaq Capital Market.
For a thorough assessment of FIXX stock, go to TipRanks’ Stock Analysis page.
